Home Ingredients VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)
Cardiovascular

VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)

Evidence Level
Moderate
3 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

VasoDrive-AP® (Kyowa Hakko USA) supplies the casein-derived lactotripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP), bioactive milk peptides with natural ACE-inhibitory activity that are studied for supporting healthy blood pressure. This is distinct from the site's generic casein-protein entry: casein protein is a bulk dietary protein, whereas VasoDrive-AP® is a concentrated source of the specific BP-active tripeptides. Honest framing: meta-analyses show a modest blood-pressure reduction with notable heterogeneity, and effects tend to be smaller and less consistent in Western/European populations than in Japanese trials.

Studied Dose Lactotripeptide trials commonly used a few mg/day of combined IPP+VPP (often ~3–10 mg/day); VasoDrive-AP® is dosed to provide a standardized tripeptide amount per manufacturer guidance.
Active Compound Lactotripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) derived from casein — VasoDrive-AP® by Kyowa Hakko USA; naturally ACE-inhibitory milk peptides.

Benefits

Healthy Blood Pressure Support

IPP and VPP have natural ACE-inhibitory activity and may help support blood pressure that is already in the normal-to-high-normal range. Honest context: pooled trial effects are modest in size and vary between populations, so VasoDrive-AP® is a supportive, not primary, blood-pressure tool.

Supported by Trial 1, Trial 2

Targeted Bioactive Peptides

Unlike bulk casein protein, VasoDrive-AP® concentrates the specific tripeptides responsible for the blood-pressure signal. This makes it a defined, standardized way to obtain IPP/VPP rather than relying on dietary dairy intake.

Supported by Trial 1, Trial 2

Vascular Function Support

By gently modulating the renin-angiotensin system, lactotripeptides may support healthy vascular tone and endothelial function. The effect is mild and best viewed as part of an overall heart-healthy lifestyle.

Supported by Trial 3, Trial 1

Well-Tolerated Milk-Peptide Source

Lactotripeptides are food-derived peptides with a long history of use in functional foods and a favorable tolerability profile, making them an option for people seeking gentle, food-based cardiovascular support.

Supported by Trial 1, Trial 3

Mechanism of action

1

ACE Inhibition

IPP and VPP inhibit angiotensin-converting enzyme (ACE), reducing conversion of angiotensin I to the vasoconstrictor angiotensin II and slowing breakdown of vasodilatory bradykinin — a mild, natural version of the mechanism used by ACE-inhibitor drugs.

2

Renin-Angiotensin Modulation

By dampening angiotensin II formation, the tripeptides can promote vasodilation and reduce vascular resistance, which underlies their modest blood-pressure effect observed in trials.

3

Proline-Rich Peptide Stability

The proline residues in IPP/VPP confer resistance to digestive proteases, allowing a fraction of these tripeptides to survive digestion and reach circulation intact — important for their bioactivity as food-derived peptides.

Clinical trials

1
Lactotripeptides and Blood Pressure (Pooled)

Meta-analysis of randomized controlled trials of IPP/VPP lactotripeptides as functional foods on blood pressure.

Pooled across lactotripeptide randomized trials.

Lactotripeptides were associated with modest reductions in systolic and diastolic blood pressure, with significant heterogeneity between studies. Supports a measured claim of healthy blood-pressure support rather than a large antihypertensive effect.

2
Lactotripeptides in European Subjects

Meta-analysis of randomized controlled trials examining whether IPP/VPP reduce systolic blood pressure specifically in European populations.

European adults across randomized trials.

The blood-pressure effect was more convincing in subjects of Asian origin and less consistent in European populations. This supports the honest, population-dependent framing for VasoDrive-AP®.

3
Milk Proteins and Peptides Review

Review of human intervention studies on the impact of milk proteins and peptides, including casein-derived lactotripeptides, on blood pressure and vascular function.

Review of human intervention studies.

The review found accumulating but variable-quality evidence for blood-pressure and vascular benefits of milk proteins/peptides, again underscoring that effects are modest and not uniformly replicated.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated as food-derived peptides.
Mild digestive upset possible.
Not suitable for people with milk-protein allergy.
Possible additive effect with blood-pressure-lowering therapy; monitor.
Limited specific safety data in pregnancy and lactation.

Important Drug interactions

ACE inhibitors (e.g., lisinopril, ramipril) — theoretical additive ACE inhibition; monitor blood pressure.
Other antihypertensives — possible additive blood-pressure lowering; monitor.
Potassium-sparing diuretics — use caution given shared renin-angiotensin effects; monitor potassium.
Generally minimal interactions outside cardiovascular medications.

More Cardiovascular Ingredients

Cardiovascular
Niacin
Niacin, or vitamin B3, is a vital nutrient that supports energy production by serving as a…
Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), an…
Cardiovascular
Potassium
Potassium is the most abundant intracellular cation in the human body and an essential min…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…

Explore Other Ingredients

Cardiovascular
Beetroot
Beetroot is a rich dietary source of inorganic nitrate, which the body converts to nitric…
Athletic Performance
L-Carnitine
L-Carnitine is a naturally-occurring amino acid derivative essential for fatty acid metabo…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a lipid-soluble compound essential to mitochondrial ATP production…

Frequently asked questions about VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)

What is the recommended dosage of VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)?

The clinically studied dose for VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP) is Lactotripeptide trials commonly used a few mg/day of combined IPP+VPP (often ~3–10 mg/day); VasoDrive-AP® is dosed to provide a standardized tripeptide amount per manufacturer guidance.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP) used for?

VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP) is studied for healthy blood pressure support, targeted bioactive peptides, vascular function support. IPP and VPP have natural ACE-inhibitory activity and may help support blood pressure that is already in the normal-to-high-normal range.

Are there side effects from taking VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)?

Reported potential side effects may include: Generally well tolerated as food-derived peptides. Mild digestive upset possible. Always consult a healthcare provider before starting any new supplement, especially if you have underlying conditions or take medications.

Does VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP) interact with medications?

Known drug interactions may include: ACE inhibitors (e.g., lisinopril, ramipril) — theoretical additive ACE inhibition; monitor blood pressure. Other antihypertensives — possible additive blood-pressure lowering; monitor. Consult a pharmacist or healthcare provider if you take prescription medications.

Is VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP) good for cardiovascular?

Yes, VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP) is researched for Cardiovascular support. IPP and VPP have natural ACE-inhibitory activity and may help support blood pressure that is already in the normal-to-high-normal range. Honest context: pooled trial effects are modest in size and vary between populations, so VasoDrive-AP® is a supportive, not primary, blood-pres…

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens. 2011;25(7):425-36. doi: 10.1038/jhh.2010.85.PubMedUsed to support: Backs the modest blood-pressure benefit: pooled lactotripeptide trials showed a statistically significant but modest reduction in blood pressure.
  2. Cicero AF, Aubin F, Azais-Braesco V, Borghi C. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens. 2013;26(3):442-9. doi: 10.1093/ajh/hps044.PubMedUsed to support: Anchors the population-dependent honest framing: BP effect was less consistent in European subjects than in those of Asian origin.
  3. Fekete AA, Givens DI, Lovegrove JA. The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies. Nutr Res Rev. 2013;26(2):177-90. doi: 10.1017/S0954422413000139.PubMedUsed to support: Supports the vascular/BP context for casein-derived peptides while noting variable study quality and modest, inconsistent effects.